Essity: A Defensive Healthcare Stock for German Investors?

Essity, the Swedish hygiene and health company behind well-known brands like Tempo, Zewa, and TENA, presents a compelling case for German investors seeking stability and dividend income. While the stock has experienced a period of stagnation, several factors suggest it could be an attractive addition to a diversified portfolio, particularly in uncertain market conditions.

Essity’s Position in the German Market

Essity maintains a significant presence in Germany, a core market for the company. From household products like Tempo handkerchiefs to specialized healthcare solutions like TENA incontinence products, a substantial portion of Essity’s sales originate from Europe, with Germany playing a key role. The company’s success in Germany is directly linked to the country’s purchasing power and healthcare spending.

Recent Performance and Challenges

In recent quarters, Essity has reported robust sales, driven by price increases and relatively stable demand. However, margins have faced pressure due to increased costs for pulp, energy, and logistics. Investors are closely monitoring the company’s ability to restore gross margins to pre-crisis levels.¹

The stock’s price trend reflects its nature as a defensive consumer and healthcare stock: it avoids dramatic peaks and crashes, instead exhibiting a sideways movement. This suggests the market is awaiting clearer signals regarding profitability and capital allocation.

Key Facts About Essity B Shares

• Security: Essity AB, Series B (hygiene and health products)
• Stock Exchange: Nasdaq Stockholm
• Currency: Swedish Krona (SEK)
• Relevance for Germany: Strong brand presence (Tempo, Zewa, TENA), key supplier to clinics, nursing homes, and retailers
• Business Segments: Tissue (household & consumer), Health & Medical Products, Professional Hygiene (B2B)
• Investment Character: Defensive consumer/healthcare stock with a dividend focus and moderate growth
• Currency Risk: SEK exposure for Euro investors

Structural Trends Favoring Essity

Several structural trends are particularly relevant for investors in German-speaking countries:

• Demographics: Germany’s aging population is increasing demand for incontinence and medical products.
• Healthcare Spending: Rising healthcare costs are offset by growing volumes, positioning Essity favorably with its strong brands and B2B contracts.
• Hygiene Standards: Increased awareness of hygiene, particularly since the pandemic, is boosting demand for hygiene products in public spaces, offices, clinics, and nursing homes.

Potential Risks for Investors

Despite the positive outlook, several risks could hinder Essity’s price performance:

• Persistent cost and wage pressures in Europe, which may not be fully passed on to customers.
• Strong competition in the household tissue sector from private labels and international players.
• Regulatory and pricing pressures within the healthcare system, particularly in Germany.

Analyst Perspectives

Investment banks and analysis houses generally view Essity as a core investment in the defensive sector. Current research notes from firms like JPMorgan, Goldman Sachs, and Scandinavian banks typically rate the stock as a “Hold” to “Buy,” depending on the time horizon and margin development assessment.²

Analysts highlight the following:

• Pros: Strong brands, reliable cash flow, pricing power in certain areas, structural growth driven by demographics and healthcare.
• Cons: Margin sensitivity to raw materials, energy, and wages; limited organic growth rates; currency risks.

Some research houses compare Essity to traditional DAX defensive stocks in the health and consumer sectors, but with slightly higher cyclicality due to its reliance on raw materials. For investors seeking diversification beyond DAX stocks, Essity offers exposure to the European hygiene sector without being solely Euro-denominated.

€400 Million Investment in R&D

The European Investment Bank (EIB) is providing €400 million in financing to support Essity’s research, development, and innovation (RDI) activities in Sweden, Germany, and France.³⁴ This investment will focus on developing more sustainable products and production processes, including replacing plastics with bio-based materials and reducing greenhouse gas emissions.

Conclusion

Essity is not a high-growth stock, but a solid, cash-generating hygiene group that becomes particularly attractive during uncertain market phases. Investors willing to monitor currency and margin risks can consider the stock as a defensive component and dividend provider within a European healthcare and consumer portfolio. The stock’s value is most appealing when market fears regarding costs or currency issues lead to undervaluation.